Trial Profile
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study of an Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Sugemalimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CStone Pharmaceuticals
- 15 Feb 2022 Status changed from active, no longer recruiting to completed.
- 29 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Oct 2021.
- 29 Jan 2021 Status changed from recruiting to active, no longer recruiting.